Landmark investment will accelerate access to cannabis-based healthcare as the UK market approaches a £1bn valuation, positioning Mamedica to support up to 100,000 patients.

NEW YORK, Sept. 23, 2025 /PRNewswire/ — Mamedica, the UK’s leading and most-trusted provider of cannabis-based prescription medicines, today announced a £4.5 million funding round led by Casa Verde, the US-based cannabis-focused venture capital firm.

Casa Verde has backed major cannabis companies including Dutchie, Metrc and Leaflink in the United States, and holds European positions in Cansativa and Sanity Group. The new capital will be used to scale Mamedica’s operations by optimising its in-house supply chain for efficiency and continuity of care, expanding access through a wider clinical network, advancing its proprietary digital healthcare platform with enhanced automation and compliance capabilities, and driving education around the integration of medical cannabis into mainstream healthcare.

Launched in 2022 by CEO and founder Jon Robson, Mamedica provides specialist treatment for chronic and neurological conditions including pain, anxiety, ADHD and depression. Its digital model enables remote consultations with specialist clinicians, with medication delivered nationwide by secure next-day courier. Since inception, Mamedica has treated over 10,000 patients, with approximately 7,500 actively under care and around 10% month-on-month growth in initial consultations. The company recorded 1,250% patient growth in 2023 and 154% in 2024 and expects to double patient numbers annually as the UK medical cannabis industry approaches £1bn in annual sales by the end of 2028.

“We’re excited to partner with Mamedica as the UK cannabis market enters a period of rapid growth,” said Karan Wadhera, Managing Partner at Casa Verde. “Mamedica’s digital-first, patient-centric model sets the standard for care in the UK and offers a blueprint for broader European expansion.”

“This funding marks a pivotal milestone in Mamedica’s mission to transform patient care in the UK,” said Jon Robson, CEO and founder of Mamedica. “The backing of Casa Verde and our private investors validates our approach and enables us to accelerate access to high-quality, regulated treatment.”

About Mamedica

Mamedica is a digital healthcare platform providing UK patients with access to cannabis-based prescription medicines across pain, psychiatry, neurology, palliative care and cancer. Following a secure video consultation, medication is dispensed and delivered nationwide via next-day courier. Founded in 2022, Mamedica prioritises patient care, safety and satisfaction through proprietary technology, specialist clinicians, experienced pharmacists and dedicated support staff.